[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sexually-transmitted-infections-sti\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sexually-transmitted-infections-sti":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100609495","phase-4-got-doxy--flipping-the-script-on-sti-pep-100609495",false,"NCT07215325","Got Doxy- 'Flipping the Script' on STI PEP","The Effects of Doxycycline on Inflammation and the Microbiome: 'Flipping the Script' on STI PEP","Inclusion Criteria:\n\n* Age \\>18 years\n* Assigned male sex at birth\n* Good general health as assessed by a clinician at the screening study visit\n* For people with HIV, on suppressive antiretroviral therapy for at least 6 months with the most recent viral load documented \\\u003C50 copies\u002Fml and the most recent cluster of differentiation 4 (CD4)\\>300cells\u002Ful\n* For people without HIV, taking oral daily, oral on-demand, or injectable pre-exposure prophylaxis for at least 3 months at the time of enrollment, with plans to continue for the duration of the study\n* Additional criteria apply\n\nExclusion Criteria:\n\n* Severe\u002Funcontrolled comorbidities that could influence immune outcomes (e.g., diabetes, hypertension, co-infections), as assessed by the investigator.\n* History of inflammatory bowel disease (IBD) or other inflammatory, infiltrative, infectious, or vascular condition involving the lower GI tract that, in the judgment of the investigators, may be worsened by study procedures or may significantly distort the anatomy of the distal large bowel.\n* Known allergy to doxycycline\n* Use of any antibiotics within 3 months before screening\n* Significant lab abnormalities at baseline visit for rectal biopsies,\n* Continued need for the following medications during the study:\n\n  1. Aspirin\n  2. Warfarin, heparin (LMW or unfractionated), platelet aggregation inhibitors, or fibrinolytic agents\n  3. Any form of rectally administered agent besides products (lubricants or douching) used for sexual intercourse\n  4. NSAIDS within 72 hours of rectal sampling procedures\n* Continued need for, or use during the 90 days before enrollment, of the following medications:\n\n  1. Systemic immunomodulatory agents\n  2. Supraphysiologic doses of corticosteroids, except for short-course corticosteroids \\\u003C7 days duration at the discretion of the investigator. (Gender affirming hormone therapy is not exclusionary.)\n  3. Use of experimental medications, vaccines, or biologicals in the 12 months before enrollment",true,"MALE","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study is being done to test the effects of doxycycline on inflammation and the bacteria in the body in people with HIV and in people on HIV pre-exposure prophylaxis. This drug is approved by the Food and Drug Administration (FDA) for the treatment of bacterial infections.\n\nThe study team will investigate whether the drug has additional effects on inflammation or on the bacteria that live in the body.",[27],"Sexually Transmitted Infections (STI)",[29,30,31,32,33],"Doxycycline post-exposure prophylaxis (doxy-PEP)","Gut inflammation","Prevention","PEP","STI","RECRUITING","2026-04-26",{"date":37,"type":38},"2026-04-30","ACTUAL",{"date":40,"type":38},"2025-10-13",{"date":42,"type":21},"2029-04-13",{"name":44,"class":45},"Emory University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100626311","california-meps-hub-100626311","NCT07433985","California MEPS Hub","California Hub for HIV\u002FSTI\u002FSUD Prevention Research With Reentry Populations","Inclusion Criteria:\n\nRCT Participants\n\n* Assigned male at birth\n* Ages 18 - 59\n* Was released from incarceration in the previous 12 months (incarceration is defined as a stay in jail, prison, or detention centers for over 24 hours)\n* Reports an SUD diagnosis or seeking SUD services at any time in the 24 months prior to enrollment\n* During the 24 months prior to enrollment, either:\n\n  1. Reports intercourse with a person assigned male at birth\n  2. Reports injection drug use\n* Has not received an HIV diagnosis (based on self-report)\n* Possesses a smartphone or plans to obtain one\n* Plans to reside within designated jurisdictions (counties) for the 9 months following enrollment\n\nCBO and agency staff participating in implementation surveys or interviews\n\n* \\>=18 years of age\n* Employed at a study site or otherwise involved with intervention implementation and\u002For maintenance OR works at an agency in the counties where the study is taking place (Los Angeles, Riverside, San Bernardino, and Alameda counties, California).\n* Willing to provide informed consent for participation.\n\nExclusion Criteria:\n\nRCT Participants:\n\n* Does not have a smart phone and is not willing to obtain one\n* Is not able to speak and understand English\n* Has insufficient reading skills to operate a mobile application on a cell phone\n\nCBO participating in implementation interviews\n\n\\- n\u002Fa","59 Years",{"count":55,"type":21},318,[57],"NA","The California Hub for HIV\u002FSUD Prevention Research with Reentry Populations addresses the question: \"Can the evidence-based MEPS intervention be adapted and implemented at a range of organizations to effectively serve a wider range of clients?\"\n\nThe Mobile Enhanced Prevention Support (MEPS) intervention was originally implemented in Los Angeles County and was proven successful in promoting biomedical HIV prevention (PrEP) uptake and preventative screenings in people who used drugs who recently left incarceration. MEPS is an evidence-based intervention for people with substance use disorders (SUD) that incorporates a client-centered planning session, including trained peer mentors, service utilization incentives, and a mobile application (GeoPass).\n\nThe study includes a randomized controlled trial (RCT) across three community partners located in Riverside and Alameda Counties. At least 300 people will be enrolled in these three counties; the first 200 will be randomized to either receive the intervention or usual care, with the final 100 all receiving the intervention. The primary implementation outcome for the study involves using an implementation science framework and assessment tools to examine MEPS's implementation. Key outcomes include how well the implementation strategies used support intervention enrollment and retention, integration with existing services in each partnering community agency, and perceived intervention acceptability, feasibility, appropriateness, and maintenance at 6- and 12-months. The primary effectiveness outcome for the study is an increase in HIV testing, PrEP uptake and adherence, and SUD service utilization at 6 months and 12 months in the MEPS compared to the usual care group. Secondary effectiveness outcomes include frequency of service use for SUDs, hepatitis C virus testing, and linkage to care for those who test positive for HIV or hepatitis C.",[60,27,61,62,63,64],"HIV Prevention","Preexposure Prophylaxis (PrEP)","Incarceration","Hepatitis C Virus (HCV)","Substance Use Disorder (SUD)",[66,67,68,69,70,71],"implementation science","contingency management","mobile health technology (mHealth)","community based participatory research","type 3 hybrid implementation effectiveness trial","randomized controlled trial","2026-04-01",{"date":74,"type":38},"2026-04-03",{"date":76,"type":38},"2025-12-01",{"date":78,"type":21},"2029-07-31",{"name":80,"class":45},"University of California, Los Angeles",3]